Madrigal Pharma (MDGL) Emerges as a High-Conviction Shorted Biotech Play Amid Clinical Momentum

Madrigal Pharma (MDGL) has captured attention among investors seeking high-risk, high-reward opportunities in the biotechnology sector, particularly among those betting against the stock’s current bearish sentiment. The company, focused on metabolic and liver diseases, has seen its short interest climb to 14.2% of the float as of the reporting period, placing it among the most heavily shorted names in the healthcare space. This metric underscores aggressive bearish positioning, particularly among institutional investors, despite recent clinical progress. The company’s lead asset, resmetirom, has demonstrated promising Phase 3 results in patients with non-alcoholic steatohepatitis (NASH), with reductions in liver fat and fibrosis observed in a pivotal trial. These data, which were publicly disclosed in late 2025, have fueled optimism that resmetirom could secure FDA approval by mid-2026. The anticipated regulatory pathway has attracted interest from both biotech-focused funds and retail traders positioning for a short squeeze. MDGL’s market cap stands at approximately $4.8 billion, with a trailing 12-month revenue of $128 million. The stock’s beta of 2.1 indicates elevated volatility compared to the broader healthcare sector, as measured by the XLV ETF. Meanwhile, its relative strength against the IHI index suggests growing investor interest, particularly in the face of a 22% decline in short interest during Q4 2025—a reversal that may signal shifting sentiment. Market impact is concentrated within the biotech subsector and among options traders. Increased options volume on MDGL, particularly out-of-the-money calls, signals anticipation of a breakout. Investors in ETFs like XLV may see indirect exposure to MDGL’s performance, especially if broader healthcare momentum shifts. The stock’s price volatility also affects trading desks and market makers managing hedging positions.